CCXI - ケモセントリックス (ChemoCentryx Inc.) ケモセントリックス

 CCXIのチャート


 CCXIの企業情報

symbol CCXI
会社名 ChemoCentryx Inc. (ケモセントリックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 ケモセントリックス(ChemoCentryx Inc.)はバイオ医薬品会社であり、自己免疫疾患、炎症性疾患や癌を治療する経口投与の治療薬の発見・開発・商品化に従事する。薬物候補のそれぞれは、その負の炎症性または抑制性応答を選択的にブロックする特定の化学誘引物質受容体に焦点を当て、免疫系の残りの部分をそのまま残す。後期化合物には、Avacopan(CCX168)とCCX140が含まれる。アバコパン(CCX168)は、C5a受容体(C5aR)を標的とする経口投与補体阻害剤であり、抗好中球細胞質自己抗体関連血管炎(AAV)、非定型溶血性尿毒症症候群(aHUS)補体3糸球体症(C3G)を補完する。CCX140は、糖尿病性腎症(DN)、慢性腎疾患(CKD)及び局所分節性糸球体硬化症(FSGS)の開発において、C-Cケモカイン受容体2型(CCR2)として知られるケモカイン受容体の経口投与阻害剤である。   ケモセントリックスは米国のバイオ医薬品企業。自己免疫疾患、炎症性疾患、癌の治療向け経口治療薬の開発、商業化に従事。抗好中球細胞質抗体の治療薬CCX168、糖尿病性腎症治療薬CCX140、ケモカイン受容体向け経口阻害剤CCX872、中等症から重症のクロ―ン病治療薬Vercirnon、炎症性腸疾患向け阻害剤CCX507の製品候補を手掛ける。   ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
本社所在地 850 Maude Avenue Mountain View CA 94043 USA
代表者氏名 Thomas J. Schall トーマス・J・ショール
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 650-210-2900
設立年月日 1997年
市場名 NASDAQ National Market System
ipoyear 2012年
従業員数 66人
url www.chemocentryx.com
nasdaq_url https://www.nasdaq.com/symbol/ccxi
adr_tso
EBITDA EBITDA(百万ドル) 15.48300
終値(lastsale) 10.6
時価総額(marketcap) 534012852.6
時価総額 時価総額(百万ドル) 574.81950
売上高 売上高(百万ドル) 89.89800
企業価値(EV) 企業価値(EV)(百万ドル) 407.47850
当期純利益 当期純利益(百万ドル) 16.80400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 ChemoCentryx Inc revenues increased 43% to $24.6M. Net loss increased 7% to $16.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 34% to $32.5M (expense) General and administrative increase of 7% to $9.4M (expense).

 CCXIのテクニカル分析


 CCXIのニュース

   Why ChemoCentryx Shares Are Rising  2022/01/19 16:29:19 Benzinga
ChemoCentryx Inc (NASDAQ: CCXI ) shares are Full story available on Benzinga.com
   ChemoCentryx''s Avacopan Scores European Approval For ANCA-Associated Vasculitis  2022/01/19 15:47:20 Benzinga
The European Union has approved ChemoCentryx Inc''s (NASDAQ: CCXI ) Tavneos (avacopan) for ANCA-associated vasculitis. The approval follows the FDA approval of Tavneos in October 2021 . The approval covers the treatment combined with a rituximab or cyclophosphamide regimen for severe, active granulomatosis polyangiitis Full story available on Benzinga.com
   Wells Fargo Pounds the Table on ChemoCentryx Stock  2022/01/19 01:22:14 TipRanks

The holy grail for a biopharma company is to get a drug approved and out to market, a feat achieved by few, considering the rigorous demands of regulators. However,

   CERS, LTRPA and PECO among after hour movers  2022/01/18 22:35:20 Seeking Alpha
Gainers: Cerus Corporation (CERS) +7%. ChemoCentryx (CCXI) +3%
   ChemoCentryx rebounds on bullish update for new ANCA vasculitis therapy  2022/01/13 17:02:05 Seeking Alpha
After four consecutive sessions of losses, ChemoCentryx <> is on the rise after Raymond James noted the latest prescriber information on the companys ANCA vasculitis drug
   Hidradenitis Suppurativa Pipeline Landscape: Novel Emerging Therapies and Key Pharmaceutical Companies Reinvigorates the Pipeline Landscape  2021/07/15 01:00:00 Benzinga
Los Angeles, July 14, 2021 (GLOBE NEWSWIRE) -- Hidradenitis Suppurativa Pipeline Landscape: Novel Emerging Therapies and Key Pharmaceutical Companies Reinvigorates the Pipeline Landscape The Hidradenitis Suppurativa pipeline landscape includes several therapies with different mechanisms of action currently being studied with great market potential. Ongoing scientific research has provided greater sophistication and a clearer understanding of the mechanisms of therapeutic interventions for Hidradenitis suppurativa. DelveInsight''s '' Hidradenitis Suppurativa Pipeline Insights '' report presents an exhaustive coverage of the available therapies, Hidradenitis Suppurativa emerging drug therapies in different phases of clinical development, key companies working to advance the Hidradenitis Suppurativa pipeline therapies, and the future market scope of the space. Some of the notable pointers extracted from the Hidradenitis Suppurativa (HS) Pipeline report: DelveInsight''s analysis depicts a robust Hidradenitis Suppurativa Pipeline with 25+ active players in the domain working on 25+ pipeline therapies.
   Is Now the Time to Buy ChemoCentryx Stock?  2021/07/10 10:44:00 The Motley Fool
Analysts following this risky biotech stock have changed their tune.
   A Risky Yet Potentially Lucrative Bet  2021/07/10 07:31:37 Bitcoin Ethereum News
The post A Risky Yet Potentially Lucrative Bet appeared on BitcoinEthereumNews.com . With shares sitting 73% into the red in 2021, its safe to say, Chemocentryx (CCXI) investors have endured a difficult year so far. The alarming decline has mostly been due
   Chemocentryx: A Risky Yet Potentially Lucrative Bet  2021/07/09 20:31:53 TipRanks
With shares sitting 73% into the red in 2021, its safe to say, Chemocentryx (CCXI) investors have endured a difficult year so far. The alarming decline has mostly bee
   (CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses?  2021/07/07 12:21:00 Business Insider Markets
SAN DIEGO, July 7, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of ChemoCentryx Inc. ("ChemoCentryx" or the "Company") ( NASDAQ: CCXI) against certain of its current and
   Leerink Partners Stick to Their Buy Rating for Chemocentryx Inc. By Investing.com  2021/04/18 11:45:17 Investing.com
Leerink Partners Stick to Their Buy Rating for Chemocentryx Inc.
   Canaccord Genuity Stick to Their Buy Rating for Chemocentryx Inc. By Investing.com  2021/04/16 10:25:01 Investing.com
Canaccord Genuity Stick to Their Buy Rating for Chemocentryx Inc.
   ChemoCentryx Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysis  2021/03/01 13:30:00 Stock Market Daily
ChemoCentryx announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs  2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.
   The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market  2021/01/26 13:07:39 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25) Abbott Laboratories (NYSE: ABT ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) (announced FDA approval for its oral lupus nephritis drug) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioNano Genomics Inc (NASDAQ: BNGO ) (reacted to positive sell-side commentary) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearpoint Neuro Inc (NASDAQ: CLPT ) DarioHealth Corp (NASDAQ: DRIO ) DermTech Inc (NASDAQ: DMTK ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (reacted to positive Phase 3 data for its COVID-19 antibody treatment bamlanivimab) Ekso Bionics Holdings Inc (NASDAQ: EKSO ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Evogene Ltd (NASDAQ: EVGN ) EXACT Sciences Corporation (NASDAQ: EXAS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Halozyme Therapeutics, Inc.

 関連キーワード  (医薬品 米国株 ケモセントリックス CCXI ChemoCentryx Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)